Chan Zuckerberg Initiative's Biohub to open new rare disease funding round

• Rare As One has engaged more than 320,000 patients and 26,000 researchers through 94 patient-led organizations, with two-thirds building research infrastructure and over half contributing to clinical trial development
• The expanded partnership with Every Cure will connect advocacy groups with AI-identified opportunities to repurpose existing medicines for diseases lacking treatment options
• The initiative is part of a broader $500 million Virtual Biology Initiative to build predictive cell models and accelerate drug discovery using artificial intelligence

Summary: Chan Zuckerberg Initiative's Biohub Expands Rare Disease Funding

Key Developments:

The Chan Zuckerberg Initiative's Biohub will launch its fourth funding round through the Rare As One Network this fall, likely opening applications in October. This cycle will target patient-led organizations focused on rare pulmonary diseases, immune disorders, and rare cancers.

Financial Commitment:

Rare As One has committed over $150 million across its first three funding cycles since launching seven years ago. The program recently announced a separate $500 million Virtual Biology Initiative aimed at building predictive cell models.

Program Impact:

The initiative has supported 94 patient-led organizations, engaging more than 320,000 patients and community members, plus 26,000 researchers. Two-thirds of funded groups have built research assets and tools, while over half have contributed to developing and launching clinical trials. Some organizations now sponsor their own trials independently.

Strategic Partnership:

Biohub is expanding its collaboration with Every Cure, a nonprofit using AI to identify drug repurposing opportunities for diseases with limited treatment options. Select patient organizations will partner with Every Cure to advance AI-identified drug candidates into patient-centered research programs. Biohub has supported Every Cure since 2023.

Market Implications:

The initiative represents a growing intersection of philanthropic capital, AI technology, and rare disease research. By empowering patient-led advocacy groups and leveraging AI for drug discovery and repurposing, the program aims to accelerate treatment development timelines and reshape traditional biomedical research paradigms. This approach could create new opportunities in the biotechnology and pharmaceutical sectors, particularly for rare disease therapeutics.